A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Abroad (travel likely)RecruitingPHASE2
Conditions
RSV Infection · RSV · Respiratory Syncytial Virus (RSV)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Center of Excellence for Pediatric Infectious Diseases and Vaccines Faculty of Medicine, Chulalongkorn University (CE-PID), Bangkok, Thailand
Contact: Principal Investigator (Napaporn Chantasrisawad, MD)Nakornping Hospital, Chiang Mai, Thailand
Contact: Principal Investigator (Rujirek Kamolrattana, MD)Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand
Contact: Principal Investigator (Tavitiya Sudjaritruk, MD)Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
Contact: Principal Investigator (Suchada Ruenglerdpong, MD)Khon Kaen Hospital, Khon Kaen, Thailand
Contact: Principal Investigator (Ussanee Srirompotong, MD)Lampang Hospital, Lampang, Thailand
Contact: Principal Investigator (Pakawadi Vuttipittayamongkol, MD)Lamphun Hospital, Lamphun, Thailand
Contact: Principal Investigator (Sangravee Juhong, MD)Maha Sarakham Hospital, Maha Sarakham, Thailand
Contact: Principal Investigator (Supawan Papakhee, MD)
Study leads
Enanta Pharmaceuticals, Inc
Study Director
Enanta Pharmaceuticals, Inc